A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients

Completed · Not applicable

Conditions studied: HIV Infections

In brief

The purpose of this study is to compare the safety and effectiveness of giving HIV-infected patients delavirdine (DLV) plus zidovudine (ZDV) plus 2 doses of indinavir (IDV) or ZDV plus IDV plus lamivudine (3TC). This study also examines how the body processes DLV when it is given in combination with other drugs.

Key facts

Study ID

NCT00002400

Run by

Pharmacia and Upjohn

People needed

45

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• HIV-1 positive.
• CD4 count above 50.
• HIV-1 RNA greater than 20,000.
• Prior Medication:
• Allowed:
• Less than 1 month prior treatment with zidovudine.

You may not qualify if…

• Prior Medication:
• Excluded:
• Prior 3TC, protease inhibitors, or non-nucleoside reverse transcriptase inhibitors.
• Prior ZDV of greater than 1 month total duration.
• Prior Treatment:
• Excluded:
• Lamivudine.
• Protease inhibitors.
• Non-nucleoside reverse transcriptase inhibitors.

Where it is running

• Pharmacia & Upjohn — Peapack, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.